QualityDipStocks / Health Care · Pharmaceuticals
AbCellera Biologics ABCL
Outside our quality screen, so we don’t track its dips. It’s 25% below its 52-week high.
Outside our quality screen, 9% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 26% from its 52-week high while revenue grew 101%
- Revenue up 101% in a year, top 2% of the 1820 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $12.25price −9%
- Off 52-wk high
- −25%
- Risk vs market
- Highbeta 2.62
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for ABCL: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much ABCL moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 6.7× the S&P 500’s.
- Beta vs S&P 500
- 2.62
- Volatility
- 86% vs 13% SPY
- Correlation SPY
- 0.39
- Correlation QQQ
- 0.39
How it ranks
Where ABCL stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 3 measures
- Free cash flow yield−3.3% · free cash flow vs market capLowest 10%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+101% · vs the 12 months beforeTop 2%of 1,814
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $12.25
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
GrowthSales grew 101% to $66M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityOperating margin widened to 44.6% in FY2022 from −290.2% in FY2023 (SEC filings).
ValuationPrice / book of 4.0×, below the 5.2× median for the 217 Health Care companies we cover.
ValuationTrades 9.2% below its Market Value of $12.25, the average price paid since the Aug 13 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$120M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $165M over the last 12 months (net income, SEC filings).
GrowthSales shrank 46% a year from FY2022 to FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter.
RiskSwings hard: beta 2.62 vs the S&P 500 and 86% yearly volatility (SPY 13%).
All fundamentals
FCF yield -3.3% · ROE -17% · Sales +101%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −3.3%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 54.41×
- Price / book
- 4.02×
- Market cap
- $3.6Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $66M
- Sales growth, 12 months
- +101.3%vs the 12 months before
- Sales growth, 3 yrs
- −46.3%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.54
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$165M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/an/m
- Net margin
- n/an/m
- FCF margin
- −180.9%
- Return on equity
- −17%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $120M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$120M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +2.4%diluted shares vs a year ago
- Stock-based comp
- $51M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From AbCellera Biologics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales −76%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-3.3%
- Gross margin−199%
- Operating marginn/m
- Return on invested capital−149%
- Return on equity−17%
- Sales growth (latest quarter vs year-ago quarter)−76%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $11.12
- 52-wk lowlowest close, 1 year$2.78−75.0%
- PriceMon Nov 2 close$11.12you are here
- Market Valueavg paid since Aug 13$12.25+10.2%
- 52-wk highhighest close, 1 year$14.82+33.3%
Momentum & 52-week range
RSI 42 · 5 days −7.9%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 9
- DateMon Nov 9, after the close
- Consensus EPS($0.18)
- Year-ago EPS($0.19)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
ABCL is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on AbCellera Biologics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.